Keywords: پاسخ کامل; CI; confidence interval; CR; complete response; DC; disease control; OS; overall survival; PD; progressive disease; PR; partial response; RECIST; Response Evaluation Criteria in Solid Tumors; SD; stable disease; STS; soft tissue sarcoma; TARE; transarteri
مقالات ISI پاسخ کامل (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پاسخ کامل; metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;
Keywords: پاسخ کامل; CR; complete response; DEE; drug-eluting embolic; ÎPBV; change in median parenchymal blood volume; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PBV; parenchymal blood volume; PD; progressive disease; PR;
Keywords: پاسخ کامل; CR; complete response; CT; computed tomography; CTCAE; common terminology criteria for adverse events; CTV; clinical target volume; 3DCRT; conventional 3D conformal radiotherapy; EBRT; external body radiotherapy; Gy; gray; IMRT; intensity-modulated radiot
Keywords: پاسخ کامل; urinary bladder neoplasms; neoplasm invasiveness; neoplasm recurrence; local; BCG vaccine; mortality; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CR; complete response; DSS; disease specific survival; MIBC; muscle invasive bladder cancer; NMIB
Keywords: پاسخ کامل; CI; confidence interval; CR; complete response; DEE; drug-eluting embolic; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PEG; polyethylene glycol; PR;
Keywords: پاسخ کامل; APC; antigen presenting cell; APOBEC; apolipoprotein B mRNA editing enzyme catalytic polypeptide-like; BRCA1/2; breast cancer 1/2; BCSS; breast cancer specific survival; B2M; β-2-microglobulin; CAF; cancer associated fibroblast; CCL; chemokine ligand; CD
Keywords: پاسخ کامل; urinary bladder neoplasms; carcinoma; programmed cell death 1 receptor; immunotherapy; APC; antigen-presenting cell; BCG; bacillus Calmette-Guérin; CD; cluster of differentiation; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4
Keywords: پاسخ کامل; Biomarkers; CDK inhibitors; Complete response; Metastatic breast cancer; Palbociclib;
Keywords: پاسخ کامل; Rectal cancer; Organ preservation; Imaging; Chemoradiotherapy; Downstaging; Complete response;
Keywords: پاسخ کامل; Bevacizumab; Carboplatin; Complete response; Paclitaxel; Spindle cell carcinoma;
Keywords: پاسخ کامل; AAA; acquired aplastic anemia; IBMF; inherited bone marrow failure; IST; immunosuppressive therapy; CSA; cyclosporine A; ATG; antithymocyte globulin; CR; complete response; PR; partial response; TA; telomerase activity; TRAP; Telomeric Repeat Amplificatio
Keywords: پاسخ کامل; Eribulin; Metastatic breast cancer; First-line; Microtubule; Dose-intensity; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; CR; complete response; DCR; disease control rate; DOR; duration of response; ECOG PS; Eas
Keywords: پاسخ کامل; thrombocytopenia; platelets; immune therapy; autoimmune disease; 4R+3Dex; 4 infusions of rituximab and three 4-day cycles of dexamethasone; CR; Complete response; ITP; Idiopathic thrombocytopenic purpura; PR; Partial response;
Keywords: پاسخ کامل; CR; complete response; DM; diabetes mellitus; NA; not available; NR; no response; PPP; palmoplantar pustulosis; PR; partial response; SAPHO; synovitis, acne, pustulosis, hyperostosis, and osteitis; TNF; tumor necrosis factor;
Keywords: پاسخ کامل; ASH; American Society of Hematology; ATAP; amphipathic tail-anchoring peptide; BAD; BCL-2-associated death promoter protein; BAK; BCL-2 homologous antagonist killer; BAX; BCL-2-associated X protein; BCL-2; B-cell lymphoma 2; BCL-w (BCL2L2); BCL-2-like pro
Keywords: پاسخ کامل; AC; adenocarcinoma; ARCON; accelerated radiotherapy with carbogen breathing and nicotinamide; CA IX; carbonic anhydrase; CCRT; concurrent chemoradiotherapy; CR; complete response; Cu-ATSM,; copper-62 labeled diacetyl-bis (N4-methylthiosemicarbazone); DFS;
Keywords: پاسخ کامل; Bx1; biopsy 1; Bx2; biopsy 2; CR; complete response; FFPE; formalin-fixed paraffin-embedded; IPA; Ingenuity Pathway Analysis; LN; lupus nephritis; NR; no response; PR; partial response;
Keywords: پاسخ کامل; ASCT; autologous stem cell transplant; CR; complete response; CT; computed tomography; DPd; daratumumab, pomalidomide, and dexamethasone; DRd; daratumumab, lenalidomide, and dexamethasone; DVd; daratumumab, bortezomib, and dexamethasone; ERd; elotuzumab,
Keywords: پاسخ کامل; kidney; carcinoma; renal cell; neoplasm metastasis; interleukin-2; molecular targeted therapy; CR; complete response; ECOG; Eastern Cooperative Oncology Group; HDIL-2; high dose IL-2; IL-2; interleukin-2; mRCC; metastatic RCC; OS; overall survival; PD; pr
Keywords: پاسخ کامل; AE; adverse event; AML; acute myeloid leukemia; APC; anaphase promoting complex; CLL; chronic lymphocytic leukemia; CPC; chromosomal passenger complex; CR; complete response; CRi; complete remission with incomplete blood count recovery; FDA; Food and Drug
Keywords: پاسخ کامل; Cáncer renal metastásico; Sunitinib; Respuesta completa; Inhibidores de la tirosina cinasaMetastatic renal cell carcinoma; Sunitinib; Complete response; Tyrosine kinase inhibitors
Keywords: پاسخ کامل; Complete response; Neoadjuvant chemoradiation; Organ preserving; Rectal cancer;
Keywords: پاسخ کامل; Rectal cancer; Complete response; Lymph nodes; Neoadjuvant treatment
Keywords: پاسخ کامل; Renal cell carcinoma; Targeted therapy; Complete response; Survival;
Keywords: پاسخ کامل; aGVHD; acute GraftVSHost Disease; CR; Complete response; EGF; Epidermal growth factor; EGFR; The EGF receptor; FS; Follistatin; GI; Gastrointestinal; HCT; Hematopoietic Cell transplantation; IL; Interleukin; ILC2; Innante Lymphoid type 2 cells; ILCs; Inna
Keywords: پاسخ کامل; Omalizumab; chronic idiopathic urticaria; chronic spontaneous urticaria; responder analysis; complete response; well-controlled urticaria; CIU; Chronic idiopathic urticaria; CSU; Chronic spontaneous urticaria; LTRA; Leukotriene receptor antagonist; UAS; U
Keywords: پاسخ کامل; CR; complete response; CTLA-4; cytotoxic lymphocyte-associated antigen 4; ECOG; Eastern Cooperative Oncology Group; EORTC; European Organization for Research and Treatment of Cancer; GAP; Good Agricultural Practice; GMP; Good Manufacturing Practice; NCCN;
Keywords: پاسخ کامل; CI; confidence interval; CR; complete response; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; IQR; interquartile range; LEM; Lipiodol and ethanol mixture; OS; overall survival; PFS; progression-free survival; TEA; transarterial ethanol ablation;
Keywords: پاسخ کامل; Afatinib; Colorectal cancer; EGFR; Combination therapy; AE; adverse events; CLX; cell line xenograft; CR; complete response; (m)CRC; (metastatic) colorectal cancer; EGFR; epidermal growth factor receptor; GI; gastrointestinal; HNSCC; head and neck squamou
Keywords: پاسخ کامل; AA; accelerated approval; ALL; acute lymphoblastic leukemia; CCyR; complete cytogenetic response; CLL; chronic lymphocytic lymphoma; CML; chronic myeloid leukemia; CRC; colorectal carcinoma; CR; complete response; CRi; complete response with incomplete bl
Keywords: پاسخ کامل; epidermal growth factor receptor; epidermal growth factor receptor inhibitor; erlotinib; squamous cell carcinoma of the skin; CR; complete response; EGFR; epidermal growth factor receptor; EGFRi; epidermal growth factor receptor inhibitors; mTOR; mechanis
Keywords: پاسخ کامل; Hyperthermia; Re-irradiation; Breast cancer recurrence; Complete response; Local control; Toxicity;
Keywords: پاسخ کامل; EC; esophageal cancer; ENI; elective nodal irradiation; IFI; involved field irradiation; RTOG; Radiation Therapy Oncology Group; CTV; clinical target volume; MHCI; major histocompatibility complex class I; CTL; cytotoxic lymphocyte; GTV; gross target volu
Keywords: پاسخ کامل; CR; complete response; CNR; contrast-to-noise ratio; GIST; gastrointestinal stromal tumor; PD; progressive disease; PDGFRA; platelet-derived growth factor receptor A; PET; positron-emission tomography; PFI; progression-free interval; PR; partial response;
Keywords: پاسخ کامل; Advanced urothelial carcinoma; Complete response; Overall survival; Partial response; Progression-free survival; Salvage systemic therapy;
Keywords: پاسخ کامل; AFP; α-fetoprotein; CI; confidence interval; CR; complete response; HCC; hepatocellular carcinoma; LRT; locoregional therapy; OR; odds ratio;
Keywords: پاسخ کامل; CI; confidence interval; CR; complete response; HNC; head and neck cancer; MW; microwave; PR; partial response; RF; radiofrequency; RT; radiation therapy;
Keywords: پاسخ کامل; CI; confidence interval; CR; complete response; CTP; Child-Turcotte-Pugh; DFS; disease-free survival; HCC; hepatocellular carcinoma; MELD; Model for End-Stage Liver Disease; mRECIST; modified Response Evaluation Criteria In Solid Tumors; SBRT; stereot
Keywords: پاسخ کامل; BRAF; v-raf murine sarcoma viral oncogene homolog; MEK; MAP kinase-ERK kinase; KIT; V-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1/PD-L1; programmed death-1/ programmed death-1 li
Keywords: پاسخ کامل; Rectal cancer; neoadjuvant chemoradiotherapy; complete response; gene signature; RNA-Seq
Keywords: پاسخ کامل; CR; complete response; FFPE; formalin-fixed, paraffin-embedded; HCC; hepatocellular carcinoma; qPCR; quantitative polymerase chain reaction; PR; partial response;
Keywords: پاسخ کامل; Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Keywords: پاسخ کامل; Immuno-oncology; T-cell receptors; Novel evaluation criteria; Ipilimumab; Nivolumab; Combinations; AE; Adverse events; APC; Antigen-presenting cell; BMS; Bristol-Myers Squibb; CR; Complete response; CTLA-4; Cytotoxic T-lymphocyte antigen 4; DTIC; Dacarbaz
Keywords: پاسخ کامل; AH; amyloid heavy chain; AL; amyloid light chain; ASCT; autologous stem cell transplant; ATTR; amyloid transthyretin; B-Dex; bortezomib and dexamethasone; BMDex; bortezomib plus melphalan and dexamethasone; BNP; brain natriuretic peptide; Bor; bortezomib;
Keywords: پاسخ کامل; ALT; alanine aminotransferase; AML; acute myeloid leukemia; AST; aspartate aminotransferase; BUN; blood urea nitrogen; CR; complete response; CRi; complete response with incomplete blood count recovery; ECOG PS; Eastern Cooperative Oncology Group Performa
Keywords: پاسخ کامل; Antiangiogenic agents; Metastatic renal cells cancer; Complete response; Sunitinib; Sorafenib; Pazopanib; Bevacizumab; Cytokines; Interferon;
Keywords: پاسخ کامل; atenolol; beta-blockers; hemangiomas; propranolol; randomized; treatment; trial; CR; complete response; ECG; electrocardiogram; HR; heart rate; IH; infantile hemangioma;
Keywords: پاسخ کامل; clinical response; extramammary Paget disease of the vulva; imiquimod; tissue-sparing surgery; treatment of recurrences; CR; complete response; EMPD; extramammary Paget disease; PR; partial response;
Keywords: پاسخ کامل; CR; complete response; EFS; event-free survival; LCR; local control rate; LFU; lost to follow-up; N; number of patients; ORR; overall response rate; OS; overall survival; PD; progressive disease; PNET; primitive neuroectodermal tumor; PR; partial response